Munich, Germany
Munich, Germany

Time filter

Source Type

Disclosed herein are recognition molecules that bind with a first binding domain to the Fc epsilon receptor (FceR) and with a second binding domain to the Fc gamma receptor IIB (FcyRIIB), as well as uses for such recognition molecules.


Disclosed herein are recognition molecules that bind with a first binding domain to the Fc epsilon receptor (FceR) and with a second binding domain to the Fc gamma receptor IIB (FcyRIIB), as well as uses for such recognition molecules.


Patent
SuppreMol | Date: 2015-02-18

An anti-FcRIIB IgG-type antibody according to the invention or a fragment or derivative thereof contains at least one of (i) a variable region of the heavy chain comprising an amino acid sequence having at least 80% identity to amino acid sequence SEQ ID NO. 1 and (ii) a variable region of the light chain comprising an amino acid sequence having at least 65% identity to amino acid sequence SEQ ID NO. 2. A further anti-FcRIIB IgG-type antibody of the invention or a fragment or derivative thereof contains at least one of (i) a variable region of the heavy chain comprising an amino acid sequence having at least 90% identity to amino acid sequence SEQ ID NO. 3 and (ii) a variable region of the light chain comprising an amino acid sequence having at least 90% identity to amino acid sequence SEQ ID NO. 4. Pharmaceutical compositions of the invention contain such antibodies, fragments or derivatives thereof and can be used for the treatment or prophylaxis of autoimmune diseases.


The present invention provides for a method for excluding a non-rheumatic disorder as cause of a musculoskeletal complaint of a subject comprising determining as to whether at least one autoantibody or antigen which is indicative for at least one rheumatic disorder is present in a sample obtained from the subject, wherein the presence of said autoantibody or antigen allows to exclude a non-rheumatic disorder as cause of a musculoskeletal complaint of a subject. Accordingly, it provides for a method that triggers the next steps in diagnosing the cause of a musculoskeletal complaint of a subject - either further diagnosis of a rheumatic disorder or of a non-rheumatic disorder to confirm the initial diagnosis. Also provided is a kit for excluding a non-rheumatic disorder as cause of a musculoskeletal complaint of a subject as well as uses of the kit.


Patent
SuppreMol | Date: 2013-10-30

The present invention relates to a nucleic acid sequence which encodes a protein of SEQ ID NO: 1; a vector comprising said nucleic acid sequence and a host cell comprising said nucleic acid sequence or said vector. The present invention also relates to a protein obtained or obtainable by expression of said nucleic acid sequence or said vector in a host cell. Furthermore, the present invention relates to a protein encoded by a nucleic acid sequence of SEQ ID NO: 6. Additionally comprised by the present invention are pharmaceutical compositions and a method of manufacturing the same.


The present invention relates in essence to an in vitro method for determining the stability, such as the shelf stability; stability over time; shelf life of a composition which comprises or essentially consists of soluble human Fc gamma receptor IIA, MB, IIIA and/or 1 MB, said method comprising the steps of contacting a surface comprising human Fc gamma receptor IIA, MB, IIIA and/or 1 MB with a set amount of aggregated human IgG; contacting said surface comprising human Fc gamma receptor IIA, MB, IIIA and/or 1 MB with a set amount of said composition of soluble human Fc gamma receptor IIA, MB, IIIA and/or 1 MB; determining the amount of aggregated human IgG which is bound to said surface comprising said human Fc gamma receptor IIA, MB, IIIA and/or 1 MB, and comparing the amount of aggregated human IgG which is bound to said surface as determined in step (c) with a reference value and (thereby) determining the stability [shelf stability; stability over time; shelf life] of said composition which comprises or essentially consists of soluble human Fc gamma receptor IIA, MB, IIIA and/or 1 MB. The present invention also relates to aggregated human IgG obtainable by a method as defined herein, as well as to the use of the mentioned aggregated human IgG in the methods of the invention.


The present invention provides an anti-FcyRIIB antibodies which, in comparison to prior art antibodies, markedly increase ITIM phosphorylation of FcyRIIB and can thus be used for the treatment or prophylaxis of autoimmune diseases.


Patent
SuppreMol | Date: 2014-10-29

The present invention relates to novel formulations of soluble Fc receptors and especially to formulations containing high concentrations of soluble FcRIIB receptor. The invention further relates to the use of such formulations as pharmaceutical compounds for the treatment of autoimmune diseases, infections and other conditions where the immune system is involved.


The present invention relates in essence to an in vitro method for determining the stability, such as the shelf stability; stability over time; shelf life of a composition which comprises or essentially consists of soluble human Fc gamma receptor IIA, IIB, IIIA and/or IIIB, said method comprising the steps of contacting a surface comprising human Fc gamma receptor IIA, IIB, IIIA and/or IIIB with a set amount of aggregated human IgG; contacting said surface comprising human Fc gamma receptor IIA, IIB, IIIA and/or IIIB with a set amount of said composition of soluble human Fc gamma receptor IIA, IIB, IIIA and/or IIIB; determining the amount of aggregated human IgG which is bound to said surface comprising said human Fc gamma receptor IIA, IIB, IIIA and/or IIIB, and comparing the amount of aggregated human IgG which is bound to said surface as determined in step (c) with a reference value and (thereby) determining the stability [shelf stability; stability over time; shelf life] of said composition which comprises or essentially consists of soluble human Fc gamma receptor IIA, IIB, IIIA and/or IIIB. The present invention also relates to aggregated human IgG obtainable by a method as defined herein, as well as to the use of the mentioned aggregated human IgG in the methods of the invention.


Patent
SuppreMol | Date: 2014-04-16

The present invention relates to novel formulations of soluble Fc receptors and especially to formulations containing high concentrations of soluble FcRIIB receptor. The invention further relates to the use of such formulations as pharmaceutical compounds for the treatment of autoimmune diseases, infections and other conditions where the immune system is involved.

Loading SuppreMol collaborators
Loading SuppreMol collaborators